0000950170-25-093996.txt : 20250703 0000950170-25-093996.hdr.sgml : 20250703 20250703172235 ACCESSION NUMBER: 0000950170-25-093996 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20250630 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250703 DATE AS OF CHANGE: 20250703 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Xenon Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001582313 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 980661854 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36687 FILM NUMBER: 251106399 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY PROVINCE COUNTRY: A1 BUSINESS PHONE: (604) 484-3300 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY PROVINCE COUNTRY: A1 8-K 1 xene-20250630.htm 8-K 8-K
false000158231300015823132025-06-302025-06-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 30, 2025

XENON PHARMACEUTICALS INC.

(Exact name of Registrant as Specified in Its Charter)

Canada

001-36687

98-0661854

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

200-3650 Gilmore Way

Burnaby, British Columbia, Canada

V5G 4W8

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (604) 484-3300

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange on which registered

Common Shares, without par value

 

XENE

 

The Nasdaq Stock Market LLC
(The Nasdaq Global Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment

of Certain Officers; Compensatory Arrangements of Certain Officers

(c) On June 30, 2025, the Board of Directors of Xenon Pharmaceuticals Inc. (the "Company") appointed Ian Mortimer, the Company's President and Chief Executive Officer, to the role of interim Chief Financial Officer and designated him as the Company's principal financial officer and principal accounting officer, effective upon the resignation of Sherry Aulin as the Company's Chief Financial Officer on June 30, 2025. No change to Mr. Mortimer's compensation was made in connection with this appointment.

The information required by Items 401(b), (d), (e) and Item 404(a) of Regulation S-K regarding Mr. Mortimer was previously reported in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 24, 2025, and such information is incorporated by reference herein.

 

Exhibit Number

Description

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 

XENON PHARMACEUTICALS INC.

Date: July 3, 2025

By:

/s/ Ian Mortimer

Ian Mortimer

Chief Executive Officer and Chief Financial Officer

 

 

 EX-101.SCH 2 xene-20250630.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 75000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink Entity Incorporation, State or Country Code Entity Incorporation State Country Code Amendment Flag Amendment Flag Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Entity Address, Postal Zip Code Entity Address Postal Zip Code Entity Address, Address Line One Entity Address Address Line1 Document Type Document Type Entity Central Index Key Entity Central Index Key Entity Address, State or Province Entity Address State Or Province Pre-commencement Tender Offer Pre Commencement Tender Offer Entity Address, City or Town Entity Address City Or Town Security Exchange Name Security Exchange Name Written Communications Written Communications Document Period End Date Document Period End Date Entity File Number Entity File Number Cover [Abstract] Security12b Title Title of 12(b) Security Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name City Area Code City Area Code Soliciting Material Soliciting Material Entity Address, Country Entity Address Country Entity Tax Identification Number Entity Tax Identification Number Local Phone Number Local Phone Number Entity Emerging Growth Company Entity Emerging Growth Company XML 4 R1.htm IDEA: XBRL DOCUMENT v3.25.2
Document and Entity Information
Jun. 30, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 30, 2025
Entity Registrant Name XENON PHARMACEUTICALS INC.
Entity Central Index Key 0001582313
Entity Emerging Growth Company false
Entity File Number 001-36687
Entity Incorporation, State or Country Code Z4
Entity Tax Identification Number 98-0661854
Entity Address, Address Line One 200-3650 Gilmore Way
Entity Address, City or Town Burnaby
Entity Address, State or Province BC
Entity Address, Country CA
Entity Address, Postal Zip Code V5G 4W8
City Area Code 604
Local Phone Number 484-3300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, without par value
Trading Symbol XENE
Security Exchange Name NASDAQ
XML 5 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 6 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 8 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.2 html 1 23 1 false 0 0 false 0 false false R1.htm 75000 - Document - Document and Entity Information Sheet http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports xene-20250630.htm xene-20250630.xsd http://xbrl.sec.gov/dei/2025 false false JSON 10 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "xene-20250630.htm": { "nsprefix": "xene", "nsuri": "http://www.xenon-pharma.com/20250630", "dts": { "inline": { "local": [ "xene-20250630.htm" ] }, "schema": { "local": [ "xene-20250630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2025": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2025": 23 }, "report": { "R1": { "role": "http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "75000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_c47ec9ba-243b-4aca-a2be-b7509ccc1da5", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "xene-20250630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c47ec9ba-243b-4aca-a2be-b7509ccc1da5", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "xene-20250630.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address Address Line1", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address City Or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security12b Title", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SolicitingMaterial", "presentation": [ "http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "WrittenCommunications", "presentation": [ "http://www.xenon-pharma.com/20250630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 11 0000950170-25-093996-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-25-093996-xbrl.zip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xene-20250630_htm.xml IDEA: XBRL DOCUMENT 0001582313 2025-06-30 2025-06-30 false 0001582313 8-K 2025-06-30 XENON PHARMACEUTICALS INC. Z4 001-36687 98-0661854 200-3650 Gilmore Way Burnaby BC CA V5G 4W8 604 484-3300 false false false false Common Shares, without par value XENE NASDAQ false